Shibao Feng

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 849 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer

Fotios Loupakis, Dongyun Yang, Linda Yau et al. · JNCI Journal of the National Cancer Institute · 2015 · 498 citations · Full text

Medicine, Oncology, Surgery +16

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Rohit Loomba, Arun J. Sanyal, Kris V. Kowdley et al. · New England Journal of Medicine · 2023 · 442 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Hartmut Goldschmidt, Rubén Niesvizky et al. · The Lancet Oncology · 2017 · 401 citations

Medicine, Oncology, Pharmacology +14

Disparities Despite Coverage

Ann S. O’Malley, Christopher B. Forrest, Shibao Feng et al. · Archives of Internal Medicine · 2005 · 144 citations

Public Health, Oncology, Preventive Medicine +17